Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of liraglutide for reducing parenteral support in short bowel syndrome
2016-004797-18Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- May 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liraglutide in short bowel syndrome (SBS) and intestinal failure (IF), sponsored by Imperial College London. Primary endpoint: Reduction in parenteral nutrition volume at 20 weeks. Status: unknown.
02
Drugs
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on 2016-004797-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004797-18.